Trupanion (TRUP) CEO Tooth Margaret Sells $26K of Stock

Margaret Tooth, the CEO of Trupanion, Inc. (NasdaqGM: TRUP), sold 1,000 shares on October 9, 2026, for $25.84 each, totaling $25,840. This sale was made under a planned transaction.

Inside Tooth's Trade

Tooth's recent sale of 1,000 shares reflects her ongoing management of personal holdings. The shares were sold at a price of $25.84, and this transaction occurred on the same day as the sale.

Other Institutional Activity in Trupanion

Several other institutional investors have also adjusted their stakes in Trupanion. Blackrock Inc. reduced its holdings by 2,177 shares, ending with 5,441,008 shares worth about $153 million. Capital World Investors increased its position by 58,616 shares, bringing its total to 3,840,269 shares valued at approximately $108 million. Meanwhile, Vanguard Portfolio Management LLC added 38,952 shares, resulting in a total of 1,801,498 shares valued at about $50.7 million.

Trupanion, Inc. Stock Up 0.6%

As of October 16, 2026, Trupanion's stock trades recently around $28.02, which is above its 50-day moving average of $27.04 but still below its 52-week high of $46.98. The stock is currently about 15.7% below its target mean price of $33.25.

Recent Earnings

Trupanion reported trailing twelve-month revenue of approximately $1.52 billion, with a net margin of 1.5% and a return on equity (ROE) of 6.1%. The next earnings report is scheduled for November 5, 2026.

Insider Buying and Selling at Trupanion, Inc.

In addition to Tooth's recent sale, other insiders have also been active. On August 28, 2026, John R. Gallagher, the Chief Operating Officer, sold 3,604 shares at $29.70, totaling $107,039. Earlier, Tooth herself sold 1,000 shares on September 11, 2026, for $25,000, at a price of $25.00 per share.

Analysts Set New Price Targets

On October 7, 2026, Cantor Fitzgerald maintained a Neutral rating on Trupanion with a price target of $30.00, down from a previous target of $34.00. The consensus recommendation for Trupanion is a "buy" with a mean price target of $33.25 based on four analyst opinions.

About Trupanion, Inc.

Trupanion, Inc. provides medical insurance for pets, focusing on cats and dogs, through a subscription model in the United States, Canada, and Europe. Founded in 2000 and based in Seattle, Washington, the company operates in two segments: Subscription Business and Other Business.

Bottom Line

Investors should keep an eye on Trupanion's upcoming earnings report on November 5, 2026, as it will provide insights into the company’s performance. Additionally, further insider transactions and institutional activity may also be worth monitoring.